Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.

被引：0
|
作者：
Swensen, Ron E.
Goff, Barbara Ann
Childs, Jennifer
Higgins, Doreen
Gooley, Theodore
Fintak, Patricia A.
Buening, Barbara
Disis, Mary L.
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[3] Univ Washington, Tumor Vaccine Grp, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5082
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
    Grisham, Rachel N.
    Moore, Kathleen N.
    Gordon, Michael S.
    Harb, Wael
    Cody, Gwendolyn
    Halpenny, Darragh F.
    Makker, Vicky
    Aghajanian, Carol A.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5525 - 5533
  • [42] Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S631
  • [43] ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.
    Olawaiye, Alexander
    Monk, Bradley J.
    Herzog, Thomas J.
    Copeland, Larry J.
    Coleman, Robert L.
    Moore, Kathleen N.
    Randall, Leslie M.
    Slomovitz, Brian M.
    O'Malley, David M.
    Eskander, Ramez Nassef
    Pothuri, Bhavana
    Van Gorp, Toon
    Pignata, Sandro
    Nicum, Shibani
    Tudor, Iulia Cristina
    Nguyen, Dorothy D.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
    Hamilton, E. P.
    Goel, S.
    Arend, R.
    Chu, C.
    Richardson, D. L.
    Corr, B.
    John, V.
    Janku, F.
    Hays, J.
    Michenzie, M.
    Reichmann, W.
    Achour, H.
    Sherman, M. L.
    Ruiz-Soto, R.
    Mathews, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S731 - S732
  • [45] A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Mullerian cancer
    Penson, Richard T.
    Berlin, Suzanne T.
    Konstantinopoulos, Panagiotis
    Krasner, Carolyn N.
    Matulonis, Ursula
    Ambrosio, Allison
    Suzin, Daphne
    Collins, Siobhan A.
    Birrer, Michael J.
    Cohen, Yael Chava
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
    Hamilton, E. P.
    Goel, S.
    Arend, R.
    Chu, C.
    Richardson, D. L.
    Diamond, J. R.
    John, V.
    Janku, F.
    Matthews, C.
    JeBailey, L.
    Kuida, K.
    Achour, H.
    Ruiz-Soto, R.
    Hays, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S629 - S630
  • [47] Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer
    Lissianskaya, A
    Gershanovich, M
    Ognerubov, N
    Golubeva, O
    Pratt, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 460S - 460S
  • [48] MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).
    Pignata, Sandro
    Lorusso, Domenica
    Scambia, Giovanni
    Sambataro, Daniela
    Tamberi, Stefano
    Cinieri, Saverio
    Mosconi, Anna Maria
    Orditura, Michele
    Bartolini, Stefania
    Arcangeli, Valentina
    Panici, Pierluigi Benedetti
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Raspagliesi, Francesco
    Salutari, Vanda
    Daniele, Gennaro
    Piccirillo, Maria Carmela
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
    Morgan, RJ
    Synold, TW
    Gandara, D
    Muggia, F
    Scudder, S
    Reed, E
    Margolin, K
    Raschko, J
    Leong, L
    Shibata, S
    Tetef, M
    Vasilev, S
    McGonigle, K
    Longmate, J
    Yen, Y
    Chow, W
    Somlo, G
    Carroll, M
    Doroshow, JH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (04) : 283 - 289
  • [50] Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
    Robert J. Morgan
    Timothy W. Synold
    David Gandara
    Franco Muggia
    Sidney Scudder
    Eddie Reed
    Kim Margolin
    James Raschko
    Lucille Leong
    Stephen Shibata
    Merry Tetef
    Steven Vasilev
    Kathryn McGonigle
    Jeff Longmate
    Yun Yen
    Warren Chow
    George Somlo
    Mary Carroll
    James H. Doroshow
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 283 - 289
12345